nference and Novo Nordisk partner on AI research into obesity, diabetes and heart disease
AI health data company nference has signed a strategic collaboration with Novo Nordisk to research cardiometabolic disease, including obesity, diabetes and cardiovascular disease.
The partnership combines Novo's clinical trial data with nference's AI platform and federated healthcare data network. Researchers from both companies will study treatment effectiveness, safety, disease progression and long-term outcomes, drawing on clinical studies, medical records, diagnostic data and other real-world evidence. Research programmes will cover clinical pharmacology, combination therapies and precision trials that track weight loss alongside whole-body health measures.
The deal also includes a framework for co-creating new ventures: AI-native companies that address unmet needs in cardiometabolic health and healthy ageing.
"We see a significant opportunity to use AI and data to deepen our understanding of cardiometabolic disease and help improve future treatments," said Jacob Sten Petersen, group vice president for R&D external innovation at Novo. nference founder and co-CEO Venky Soundararajan said the companies aim to turn discoveries into therapeutic opportunities and new ventures, according to nference.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI in Europe or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 17 AI echo analysis lifts detection of a hard-to-diagnose heart failure type to 78% Nov 17 Astromech acquires Form Bio in $230 million all-stock deal Nov 17 The Rx Assistant launches Builder, a no-code platform for pharma AI experiences Nov 17 Isomorphic Labs raises $5 billion Series C for AI drug design Nov 17 OpenAI says its computer-use agents can handle clinicians' EHR tasks, with CVS Health and Cigna among usersLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Boehringer Ingelheim and Microsoft to Study Digital Patient Twins
iReprogram and University of Michigan Launch AI Diabetes Cell Initiative
Revive Health and FitOn Health Combine Into AI Healthcare Platform
Dyania Health and Nvidia bring clinical reasoning AI inside hospital networks
Novo Nordisk Foundation Funds Nordic AI Grid Research
Daily AI Brief: the AI news that matters, in your inbox.